IPOs continue to bustle as three more biotechs prepare to make the Nasdaq leap
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
The biotech IPO market continues to charge full-steam ahead, with three more companies submitting their Nasdaq pitches to the SEC late Friday.
The leaders among the pack are Adagio Therapeutics and Castle Creek Biosciences, each penciling in $100 million initially. Following up the rear is Eliem Therapeutics, jotting down $80 million for its raise estimate less than six months after launching out of RA Capital’s incubator.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.